News
October 20, 2022

Regenstrief, IDOH collaborating on flu data and analysis for public health

Federal funding supports continuation of exceptional public-private partnership

Regenstrief Institute and the Indiana Department of Health are collaborating on an influenza surveillance data pilot study to provide in-depth data and analysis of the spread of Influenza in Indiana, similar to how Regenstrief has provided data on COVID-19.

The data will be presented as a key component to inform state and local leaders as they address the health and welfare of Hoosiers during the flu season. Goals for the data include identifying patterns and hot spots throughout Indiana. The added capabilities will signal governmental and health systems’ leadership to enhance resources and patient care in specific areas of Indiana accordingly.

The partnership is supported by a $100,000 grant from the Centers for Disease Control and Prevention and the Council of State and Territorial Epidemiologists.

“The Regenstrief Institute and Indiana Department of Health partnership has been a highly effective in responding to the COVID pandemic,” said Shaun Grannis, M.D., M.S., vice president for data and analytics for Regenstrief. “This project is important to the health of Hoosiers and is a testament to the quality of the work that these two teams are capable of, including compiling and analyzing large amounts of data to enhance public health in Indiana.

“This is a natural continuation of this exceptional, long-term partnership,” Dr. Grannis continued. “The State Department of Health and Regenstrief have worked together on a number of high profile and impactful initiatives, including Indiana’s COVID response, the public health emergency surveillance system, electronic laboratory reporting, human papillomavirus (HPV) education, traumatic brain injury and a number of other consequential projects important to Indiana and beyond.”

A team including Regenstrief and IDOH is meeting on a regular basis to review, categorize and analyze data and inform stakeholders.

About Regenstrief Institute
Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.

 

Related News

Johanne Eliacin and Sophia Wang

Factors influencing participation of Black and White Americans in Alzheimer’s disease biomarker research

Regenstrief researcher leads study of barriers to participation and drivers of engagement The use of Alzheimer’s disease (AD) biomarkers

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Study also finds less severe disease during BA.4/BA.5 predominance compared to earlier Omicron variants A multi-state study from the

Dr. Kurt Kroenke at the 2023 Indianapolis Business Journal's Health Care Heroes Awards Breakfast

IBJ Honors Regenstrief research scientist with Heath Care Hero Award 

The Indianapolis Business Journal (IBJ) honored Regenstrief Research Scientist Kurt Kroenke, M.D., MACP, as a Health Care Hero at

LOINC Logo

LOINC 2.74 Release Webinar scheduled for spring 2023

LOINC® from Regenstrief Institute will host an educational webinar for the February 2023 2.74 release of new concepts, scheduled